News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–28
Matches
28
Sources here
9
Companies here
2
Search results Stored financial headlines

Active search

28 matching headlines

Ticker or company: BLRXMain company stories
Clear
Latest

TradingKey Earnings

BioLine RX Ltd (BLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

BioLine RX Ltd (BLRX) has an earnings forecast score of 8.00, ranking 171 out of 387 in its industry. The average price target is $26.00, with a high of $40.00 and a low of $12.00, suggesting a strong buy based on analyst ratings. The expected revenue for the next quarter is 477.00K.

Main company 🇺🇸 United States
Read at TradingKey
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingView Market update Main company 🇮🇱 Israel

Price to sales forward of BioLineRX Ltd. – TASE:BLRX

This article focuses on the "Price to sales forward" metric for BioLineRX Ltd. (TASE:BLRX). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance specifically concerning its price-to-sales ratio. No specific values or detailed analysis are …

BLRX main company BLRX main company
Sharemaestro market context Trend signal active 52 weeks -28.6% · Next-week setup negative 29.1% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

BioLine RX Ltd (BLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of BioLine RX Ltd (BLRX), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 3.60, indicating it's suitable for range-bound swing trading between resistance at 3.15 and …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Deals and strategy Main company 🇺🇸 United States

BioLine RX Ltd (BLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of BioLine RX Ltd's (BLRX) dividends and stock splits. It states that BLRX has not distributed any dividends in the past five years. However, it lists multiple instances of a 40-to-1 merger stock split scheduled for January 17, 2025.

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

BioLine RX Ltd (BLRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of the shareholder structure for BioLine RX Ltd (BLRX), listing major individual and institutional holders. It outlines the proportional holdings of entities like Hong Seng Technology Ltd and Citadel Advisors LLC, and categorizes shareholder types by Corporation, Hedge …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇮🇱 Israel

BioLineRX Ltd. Revenue Breakdown – TASE:BLRX

BioLineRX Ltd. (TASE:BLRX) generated 3.76 million ILS in total revenue last year. Its primary revenue segment, Oncology and Hematology, contributed 4.07 million ILS, a significant decrease from the 107.13 million ILS it brought in the previous year. The United States was the largest geographical …

BLRX main company BLRX main company
Sharemaestro market context Trend signal active 52 weeks -28.6% · Next-week setup negative 29.1% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

BioLine RX Ltd (BLRX) Financial Health: Profitability & Balance Sheet Analysis

BioLine RX Ltd (BLRX) currently holds a weak financial health score of 5.69, ranking 334 out of 386 in its industry, indicating low operating efficiency. The company's recent quarterly revenue saw a 98.35% year-over-year decrease, and net profit declined by 29.84% year-over-year. Key financial …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Price to sales forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2

The article focuses on the "Price to sales forward" metric for BioLineRX Ltd. Sponsored ADR (SWB:YP2), a pharmaceutical company listed on the Stuttgart Stock Exchange. It appears to be a stub or a section of a financial data display, indicating the specific financial metric …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

BLRX|BioLine RX Ltd|Price:2.870|Chg%:-0.010

This article provides a comprehensive stock analysis of BioLine RX Ltd (BLRX), highlighting its stable fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple analyst "Buy" ratings with a target price of …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Preclinical Ovarian Cancer Data Show GLIX1-PARP Synergy

BioLineRx and Hemispherian announced that preclinical data demonstrating a strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer will be presented as an e-Poster at ESMO 2026. This is significant because HR-proficient tumors represent an underserved patient population …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026

BioLineRx and Hemispherian AS will present preclinical data on GLIX1 at the 2026 European Society for Medical Oncology Annual Congress. The data shows GLIX1, a TET2 activator, synergizes with PARP inhibitors in HR-proficient ovarian cancer cell lines, a type of cancer where PARP inhibitors …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

BioLineRx (BLRX) Q4 2024 earnings summary

BioLineRx (BLRX) reported a significant strategic shift in Q4 2024, focusing on lean drug development in oncology and rare diseases by shutting down U.S. commercial operations and reducing annual cash burn by over 70%. The company entered an exclusive licensing agreement for motixafortide (APHEXDA) …

BLRX main company
Sharemaestro market context Price below Trend Line 52 weeks -26.2% · Next-week setup negative 42.0% BLRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context